Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02470585 · ClinicalTrials.gov registry record · Phase 3
Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase 3 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,140
- Enrollment target
NCT02470585 is a Phase 3 study that was terminated before completion, run by AbbVie. The registered enrollment target is 1,140 participants.
The verdict
NCT02470585, a Phase 3 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,140 participants
- Enrollment target
Study Summary
The primary objective of the study was to evaluate whether progression-free survival (PFS) was prolonged with the addition of veliparib to standard platinum-based chemotherapy (carboplatin/paclitaxel \[C/P\]) and continued as maintenance therapy compared with chemotherapy alone.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Veliparib
- OTHER Placebo to Veliparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,140 participants |
| Start Date | 2015-07-14 |
| Est. Completion | 2023-10-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02470585
The ClinicalTrials.gov registry entry for NCT02470585 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT02470585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02470585 about?
NCT02470585 is a clinical study titled "Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". The primary objective of the study was to evaluate whether progression-free survival (PFS) was prolonged with the addition of veliparib to standard platinum-based chemotherapy (carboplatin/paclitaxel \[C/P\]) and continued as maintenance therapy compared with chemotherapy alone.
What is the current status of trial NCT02470585?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,140 participants. The study started on 2015-07-14. Estimated completion is 2023-10-05.
What interventions are being tested in trial NCT02470585?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Veliparib (DRUG), Placebo to Veliparib (OTHER).
Who is sponsoring clinical trial NCT02470585?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.